

# Clinical trials of glibenclamide

TrialResults-center [www.trialresultscenter.org](http://www.trialresultscenter.org)

## 1 diabetes type 2

| Trial  | Treatments   | Patients  | Trials design and methods       |
|--|--|---|---------------------------------|
| <b>glibenclamide vs c (add on MET)</b>                   |  |   |                                 |
| <b>Hermann , 1991</b><br>n=NA<br>follow-up: 6 months     | metformin + glibenclamide<br>versus<br>metformin   | patients with non-insulin-dependent<br>diabetes mellitus                                      | Parallel groups                 |
| <b>glibenclamide vs control (add on MET)</b>             |  |   |                                 |
| <b>Marre (ass) , 2002</b><br>n=NA<br>follow-up: 16 weeks | metformin-glibenclamide 500 mg/2.5 mg<br>or metformin-glibenclamide 500 mg/5 mg,<br>titrated with the intention to achieve<br>fasting plasma glucose (FPG) <or = 7<br>mmol/l<br>versus<br>metformin 500 mg,        | patients with Type 2 diabetes mellitus<br>inadequately controlled by metformin<br>monotherapy | Parallel groups<br>double-blind |
| <b>Tosi , 2003</b><br>n=NA<br>follow-up: 6 months        | metformin 400 to 2,400 mg/d +<br>glibenclamide 2.5 to 15 mg/d<br>versus<br>metformin (500 to 3,000 mg/d),  | -   | Cross over<br>double-blind      |
| <b>glibenclamide vs rosiglitazone (add on MET)</b>       |  |   |                                 |
| <b>Garber , 2006</b><br>n=NA<br>follow-up: 24 weeks      | metformin-glibenclamide 500/2.5 mg<br>tablets (initial daily dose 1000/5 mg)<br>versus<br>metformin 500 mg plus rosiglitazone 4 mg<br>(initial daily dose 1000-2000 mg + 4 mg,<br>depending on previous treatment) | patients with type 2 diabetes inadequately<br>controlled on metformin monotherapy             | double-blind                    |

More details and results :

- antidiabetic drugs for diabetes type 2 in all types of patients at <http://www.trialresultscenter.org/go-Q81>
- insulin secretagogues for diabetes type 2 in all type of patients at <http://www.trialresultscenter.org/go-Q409>
- insulin secretagogues - sulfonylureas for diabetes type 2 in all type of patients at <http://www.trialresultscenter.org/go-Q483>
- antidiabetic drugs for diabetes type 2 in patients inadequately controlled on monotherapy at <http://www.trialresultscenter.org/go-Q512>

## References

### **Hermann, 1991:**

Hermann LS, Bitzn PO, Kjellstrm T, Lindgrde F, Scherstn B Comparative efficacy of metformin and glibenclamide in patients with non-insulin-dependent diabetes mellitus. *Diabete Metab* 1991;17:201-8 [[1936477](#)]

### **Marre (ass), 2002:**

Marre M, Howlett H, Lehert P, Allavoine T Improved glycaemic control with metformin-glibenclamide combined tablet therapy (Glucovance) in Type 2 diabetic patients inadequately controlled on metformin. *Diabet Med* 2002;19:673-80 [[12147149](#)]

### **Tosi, 2003:**

Tosi F, Muggeo M, Brun E, Spiazzi G, Perobelli L, Zanolin E, Gori M, Coppini A, Moghetti P Combination treatment with metformin and glibenclamide versus single-drug therapies in type 2 diabetes mellitus: a randomized, double-blind, comparative study. *Metabolism* 2003;52:862-7 [[12870162](#)]

### **Garber, 2006:**

Garber A, Klein E, Bruce S, Sankoh S, Mohideen P Metformin-glibenclamide versus metformin plus rosiglitazone in patients with type 2 diabetes inadequately controlled on metformin monotherapy. *Diabetes Obes Metab* 2006;8:156-63 [[16448519](#)] [10.1111/j.1463-1326.2005.00570.x](#)

Entry terms: glyburide, Glyburide, Glybenclamide, Glibenclamide, Diabeta, Euglucon 5, Neogluconin, HB-419, HB 419, HB419, HB-420, HB 420, HB420, Maninil, Micronase, Daonil, Euglucon N, , 4-transhydroxy glyburide, , Glucovance, Glyburide-metformin,